Selpercatinib – a new option for a precision approach to the treatment of medullary thyroid cancer

Selpercatinib – a new option for a precision approach to the treatment of medullary thyroid cancer

Introduction. Multikinase inhibitors are used to treat nonresectable locally advanced and/or metastatic medullary thyroid cancer (MTC). However  they are characterized by high toxicity associated with kinase inhibition. Selective RET inhibitor selpercatinib demonstrates high selectivity and toleranc...

Full description

Saved in:
Bibliographic Details
Main Authors: A. K. Plugar, N. V. Severskaya, P. A. Isaev, Yu. A. Panaseykin, V. V. Polkin, L. N. Vatina, T. A. Agababyan, S. А. Ivanov, A. D. Kaprin
Format: Article
Language:Russian
Published: ABV-press 2024-12-01
Series:Опухоли головы и шеи
Subjects:
medullary thyroid cancer
selpercatinib
ret gene mutations
targeted therapy
progression-free survival
Online Access:https://ogsh.abvpress.ru/jour/article/view/1028
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://ogsh.abvpress.ru/jour/article/view/1028

Similar Items